{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T05:54:16Z","timestamp":1781848456092,"version":"3.54.5"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T00:00:00Z","timestamp":1780099200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T00:00:00Z","timestamp":1780099200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Canc Educ"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Chimeric antigen receptor t-cell (CAR T) therapy is a promising treatment option for patients with various types of leukemia and lymphoma, yet little is known about oncologists\u2019 attitudes, knowledge, and referral patterns for this therapy. Our goal was to identify potential gaps in Florida oncologists\u2019 attitudes, knowledge, and referral patterns for CAR T in patients with diffuse large b-cell lymphoma, transformed follicular lymphoma, primary mediastinal b-cell lymphoma, and acute lymphoblastic leukemia. Oncologists and Hematologists in Florida were identified from the American Medical Association\u2019s Physician Masterfile (n=771) and invited to complete a survey measuring attitudes and knowledge about CAR T and referral patterns between August 2020-October 2020. We received 67 completed surveys (10% response rate). Results were quantified using descriptive statistics. Of those who completed surveys, physicians in our study indicated moderate confidence in CAR T efficacy (49.2%), toxicity (53.8%), and indications (60%). Physicians reported frequently discussing CAR T with patients (59.4%) and indicated experiencing patient concerns about safety\/toxicity of CAR T (31.7%) and concerns about cost\/insurance coverage (39.7%). Educational materials are not frequently utilized by physicians when discussing CAR T with patients; 73% indicated they never\/rarely have materials available at clinic visits. Our study is among the first to assess oncologist\u2019s attitudes, knowledge, and referral patterns of CAR T therapy for patients with diffuse large B-Cell Lymphoma. Efforts are needed to educate community oncologists about CAR T and develop educational materials for patients to aid in decision making about CAR T therapy and improve physician confidence and referral patterns.<\/jats:p>","DOI":"10.1007\/s13187-026-02894-1","type":"journal-article","created":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T06:03:48Z","timestamp":1780121028000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Understanding Physician Referral for Chimeric Antigen Receptor T-Cell (CAR-T) Therapy"],"prefix":"10.1007","author":[{"given":"Brandon","family":"Blue","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5591-6417","authenticated-orcid":false,"given":"Paige","family":"Lake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Pidala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Jim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick L.","family":"Locke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Vadaparampil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,30]]},"reference":[{"key":"2894_CR1","doi-asserted-by":"crossref","unstructured":"Kanas G, Ge W, Quek RGW et al (2021) Epidemiology of diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) in the United States and Western Europe: population-level projections for 2020\u20132025. Leuk Lymphoma 63(1):1\u201310","DOI":"10.1080\/10428194.2021.1975188"},{"key":"2894_CR2","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1182\/blood-2005-06-2508","volume":"107","author":"LM Morton","year":"2006","unstructured":"Morton LM, Wang SS, Devesa SS et al (2006) Lymphoma incidence patterns by WHO subtype in the United States, 1992\u20132001. Blood 107:265\u2013276","journal-title":"Blood"},{"issue":"Suppl 5","key":"2894_CR3","doi-asserted-by":"publisher","first-page":"v116","DOI":"10.1093\/annonc\/mdv304","volume":"26","author":"H Tilly","year":"2015","unstructured":"Tilly H, Gomes da Silva M, Vitolo U et al (2015) Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 26(Suppl 5):v116\u2013v125","journal-title":"Ann Oncol"},{"key":"2894_CR4","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1111\/bjh.15412","volume":"182","author":"C Gisselbrecht","year":"2018","unstructured":"Gisselbrecht C, Van Den Neste E (2018) How I manage patients with relapsed\/refractory diffuse large B cell lymphoma. Br J Haematol 182:633\u2013643","journal-title":"Br J Haematol"},{"key":"2894_CR5","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu SS, Locke FL, Bartlett NL et al (2017) Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. N Engl J Med 377:2531\u20132544","journal-title":"N Engl J Med"},{"key":"2894_CR6","first-page":"664","volume":"16","author":"SL Maude","year":"2018","unstructured":"Maude SL (2018) Tisagenlecleucel in pediatric patients with acute lymphoblastic leukemia. Clin Adv Hematol Oncol 16:664\u2013666","journal-title":"Clin Adv Hematol Oncol"},{"key":"2894_CR7","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","volume":"382","author":"M Wang","year":"2020","unstructured":"Wang M, Munoz J, Goy A et al (2020) KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma. N Engl J Med 382:1331\u20131342","journal-title":"N Engl J Med"},{"key":"2894_CR8","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","volume":"384","author":"NC Munshi","year":"2021","unstructured":"Munshi NC, Anderson LD Jr., Shah N et al (2021) Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma. N Engl J Med 384:705\u2013716","journal-title":"N Engl J Med"},{"key":"2894_CR9","doi-asserted-by":"publisher","first-page":"8005","DOI":"10.1200\/JCO.2021.39.15_suppl.8005","volume":"39","author":"SZ Usmani","year":"2021","unstructured":"Usmani SZ, Berdeja JG, Madduri D et al (2021) Ciltacabtagene autoleucel, a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T-cell (CAR-T) therapy, in relapsed\/refractory multiple myeloma (R\/R MM): Updated results from CARTITUDE-1. J Clin Oncol 39:8005\u20138005","journal-title":"J Clin Oncol"},{"key":"2894_CR10","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1080\/13696998.2018.1529674","volume":"21","author":"JA Roth","year":"2018","unstructured":"Roth JA, Sullivan SD, Lin VW et al (2018) Cost-effectiveness of axicabtagene ciloleucel for adult patients with relapsed or refractory large B-cell lymphoma in the United States. J Med Econ 21:1238\u20131245","journal-title":"J Med Econ"},{"key":"2894_CR11","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1200\/JCO.18.02079","volume":"37","author":"JK Lin","year":"2019","unstructured":"Lin JK, Muffly LS, Spinner MA et al (2019) Cost effectiveness of chimeric antigen receptor T-cell therapy in multiply relapsed or refractory adult large B-cell lymphoma. J Clin Oncol 37:2105\u20132119","journal-title":"J Clin Oncol"},{"key":"2894_CR12","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.2105\/AJPH.86.10.1481","volume":"86","author":"K Kenward","year":"1996","unstructured":"Kenward K (1996) The scope of the data available in the AMA\u2019s Physician Masterfile. Am J Public Health 86:1481\u20131482","journal-title":"Am J Public Health"},{"key":"2894_CR13","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1097\/00001888-200609000-00017","volume":"81","author":"GL Freed","year":"2006","unstructured":"Freed GL, Nahra TA, Wheeler JR (2006) Counting physicians: inconsistencies in a commonly used source for workforce analysis. Acad Med 81:847\u2013852","journal-title":"Acad Med"},{"key":"2894_CR14","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.3389\/fonc.2020.01227","volume":"10","author":"A Harden","year":"2020","unstructured":"Harden A, Ragoonanan D, Anildes-Gubman D et al (2020) Chimeric Antigen Receptor, Teamwork, Education, Assessment, and Management (CAR-TEAM): A Simulation-Based Inter-professional Education (IPE) Intervention for Management of CAR Toxicities. Front Oncol 10:1227","journal-title":"Front Oncol"},{"key":"2894_CR15","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.6004\/jnccn.2021.0054","volume":"19","author":"AD Zelenetz","year":"2021","unstructured":"Zelenetz AD, Gordon LI, Chang JE et al (2021) NCCN guidelines\u00ae insights: B-cell lymphomas, version 5.2021: featured updates to the NCCN guidelines. J Natl Compr Canc Netw 19:1218\u20131230","journal-title":"J Natl Compr Canc Netw"},{"key":"2894_CR16","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1177\/1043454216655983","volume":"33","author":"W Landier","year":"2016","unstructured":"Landier W, Ahern J, Barakat LP et al (2016) Patient\/Family Education for Newly Diagnosed Pediatric Oncology Patients. J Pediatr Oncol Nurs 33:422\u2013431","journal-title":"J Pediatr Oncol Nurs"},{"key":"2894_CR17","doi-asserted-by":"crossref","unstructured":"Dhawale T, Johnson PC, Boateng K et al (2024) Communication About Chimeric Antigen Receptor T-Cell (CAR-T) Therapy. Transplantation and Cellular Therapy, Official Publication of the American Society for Transplantation and. Cell Ther 30(4):402.e1\u2013402.e12","DOI":"10.1016\/j.jtct.2024.01.069"},{"key":"2894_CR18","doi-asserted-by":"crossref","unstructured":"Hall AG, Duenas DM, Voutsinas J et al (2024) Perspectives of pediatric oncologists on referral for CAR-T therapy: a mixed methods pilot study. JNCI Cancer Spectr 8(4) pkae063","DOI":"10.1093\/jncics\/pkae063"},{"key":"2894_CR19","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1002\/pon.2022","volume":"21","author":"GP Quinn","year":"2012","unstructured":"Quinn GP, Vadaparampil ST, Malo T et al (2012) Oncologists\u2019 use of patient educational materials about cancer and fertility preservation. Psychooncology 21:1244\u20131249","journal-title":"Psychooncology"},{"key":"2894_CR20","first-page":"314","volume":"49","author":"PE Terry","year":"2000","unstructured":"Terry PE, Healey ML (2000) The physician\u2019s role in educating patients. A comparison of mailed versus physician-delivered patient education. J Fam Pract 49:314\u2013318","journal-title":"J Fam Pract"},{"key":"2894_CR21","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1001\/jama.1995.03530090032018","volume":"274","author":"DA Davis","year":"1995","unstructured":"Davis DA, Thomson MA, Oxman AD et al (1995) Changing physician performance. A systematic review of the effect of continuing medical education strategies. JAMA 274:700\u2013705","journal-title":"JAMA"},{"key":"2894_CR22","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1056\/NEJMp078190","volume":"357","author":"PR Orszag","year":"2007","unstructured":"Orszag PR, Ellis P (2007) The challenge of rising health care costs\u2013a view from the Congressional Budget Office. N Engl J Med 357:1793\u20131795","journal-title":"N Engl J Med"},{"key":"2894_CR23","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1001\/jama.2019.10194","volume":"322","author":"C Jacobson","year":"2019","unstructured":"Jacobson C, Emmert A, Rosenthal MB (2019) CAR T-cell therapy: a microcosm for the challenges ahead in medicare. JAMA 322:923\u2013924","journal-title":"JAMA"},{"key":"2894_CR24","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1182\/blood-2021-146032","volume":"138","author":"R Cusatis","year":"2021","unstructured":"Cusatis R, Tan I, Piehowski C et al (2021) Worsening Financial Toxicity Among Patients Receiving Chimeric Antigen Receptor t-Cell (CAR-T) Therapy: A Mixed Methods Longitudinal Study. Blood 138:567\u2013567","journal-title":"Blood"},{"key":"2894_CR25","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1186\/s13063-021-05121-y","volume":"22","author":"G Castillo","year":"2021","unstructured":"Castillo G, Lalu M, Asad S et al (2021) Hematologists\u2019 barriers and enablers to screening and recruiting patients to a chimeric antigen receptor (CAR) T cell therapy trial: a theory-informed interview study. Trials 22:230","journal-title":"Trials"},{"key":"2894_CR26","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1093\/fampra\/cmn097","volume":"26","author":"C Thorpe","year":"2009","unstructured":"Thorpe C, Ryan B, McLean SL et al (2009) How to obtain excellent response rates when surveying physicians. Fam Pract 26:65\u201368","journal-title":"Fam Pract"},{"key":"2894_CR27","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1038\/s41571-024-00948-1","volume":"21","author":"SA Jazowski","year":"2024","unstructured":"Jazowski SA, Nayak RK, Dusetzina SB (2024) The high costs of anticancer therapies in the USA: challenges, opportunities and progress. Nat Rev Clin Oncol 21:888\u2013899","journal-title":"Nat Rev Clin Oncol"},{"key":"2894_CR28","first-page":"440","volume":"29","author":"MS Hoffmann","year":"2023","unstructured":"Hoffmann MS, Hunter BD, Cobb PW et al (2023) Overcoming Barriers to Referral for Chimeric Antigen Receptor T Cell Therapy in Patients with Relapsed\/Refractory Diffuse Large B Cell Lymphoma. Transpl Cell Ther 29:440\u2013448","journal-title":"Transpl Cell Ther"},{"key":"2894_CR29","doi-asserted-by":"publisher","first-page":"e71562","DOI":"10.1002\/cam4.71562","volume":"15","author":"DS Abou","year":"2026","unstructured":"Abou DS, Thalib HI, Akil F et al (2026) Bispecific Antibodies Versus Chimeric Antigen Receptor T-Cell Therapy in Relapsed\/Refractory Diffuse Large B-Cell Lymphoma: A Comparative Narrative Review of Efficacy, Safety, and Accessibility. Cancer Med 15:e71562","journal-title":"Cancer Med"},{"key":"2894_CR30","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1182\/blood.2023023419","volume":"144","author":"J Kim","year":"2024","unstructured":"Kim J, Cho J, Lee MH et al (2024) CAR T cells vs bispecific antibody as third- or later-line large B-cell lymphoma therapy: a meta-analysis. Blood 144:629\u2013638","journal-title":"Blood"},{"key":"2894_CR31","first-page":"100328","volume":"17","author":"DA Sallman","year":"2022","unstructured":"Sallman DA, Bejar R, Montalban-Bravo G et al (2022) Improving patient understanding and outcomes in myelodysplastic syndromes - An animated patient guide to MDS with visual formats of learning. Leuk Res Rep 17:100328","journal-title":"Leuk Res Rep"}],"updated-by":[{"DOI":"10.1007\/s13187-026-02931-z","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:00:00Z","timestamp":1781827200000}}],"container-title":["Journal of Cancer Education"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13187-026-02894-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13187-026-02894-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13187-026-02894-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T05:40:52Z","timestamp":1781847652000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13187-026-02894-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,30]]},"references-count":31,"alternative-id":["2894"],"URL":"https:\/\/doi.org\/10.1007\/s13187-026-02894-1","relation":{},"ISSN":["0885-8195","1543-0154"],"issn-type":[{"value":"0885-8195","type":"print"},{"value":"1543-0154","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,30]]},"assertion":[{"value":"4 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s13187-026-02931-z","URL":"https:\/\/doi.org\/10.1007\/s13187-026-02931-z","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. Blue has the following COIs to report: Consultant\/Advisory Board: Bristol Meyers Squibb; Takeda. Speakers Bureau\/Honoraria: Johnson & Johnson; Kite; Pfizer. Dr. Locke has the following COIs to report: Scientific Advisory Role\/Consulting Fees: A2, Adaptive Biotechnologies, Allogene, Amgen, Astra-Zeneca, Bluebird Bio, BMS, Boxer Capital Management, Calibr, Caribou Biosciences, CytoArt (BioSwan Laboratories), EcoR1 Capital, Evoke Incisive Health Limited, Gerson Lehrman Group (GLG), Iovance, Kite Pharma, Janssen (J&J), Legend Biotech, Miltenyi, Novartis, Pagona Health, Pfizer, Poseida, Regeneron Clinical Sciences, SanaData Safety Monitoring Board: Data and Safety Monitoring Board for the National Cancer Institute (NCI), Safety Oversight CAR T-cell Therapies Committee.Research Contracts or Grants to my Institution for Service: 2SeventyBio (Institutional), Allogene (Institutional), BMS (Institutional), Incyte (Institutional), Kite Pharma (Institutional), Leukemia and Lymphoma Society Scholar in Clinical Research (PI: Locke), Mark Foundation, National Cancer Institute (NCI)Patents, Royalties, Other Intellectual Property: Several patents held by the institution in my name (unlicensed) in the field of cellular immunotherapy.Education or Editorial Activity: Aptitude Health, ASH, ASTCT, Clinical Care Options Oncology, Society for Immunotherapy of Cancer.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}